BBOT vs KEYS · $610.4M cap vs P/E 57, rev $4.98B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
BBOT does not have a complete income-statement cache yet.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
BBOT currently screens at market cap $610.4M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the BBOT and KEYS stock pages for the full models.
Not investment advice.